Cancer Research UK And AstraZeneca Sign Deal To Trial First-of-Kind Cancer Drug
Cancer Research UK And AstraZeneca Sign Deal To Trial First-of-Kind Cancer Drug
Cancer Research UK and Cancer Research Technology – the charity’s development and commercialisation arm – have reached an agreement with AstraZeneca to take compound AZD-3965 – a first-of-its-kind experimental drug to potentially treat a range of cancers- into clinical trial. AZD-3965 targets the monocarboxylate transporter 1 (MCT1)* which is essential in cell metabolism. Blocking this …
Read more on Medical News Today